{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:22:50Z","timestamp":1792797770907,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,3,30]],"date-time":"2014-03-30T00:00:00Z","timestamp":1396137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s11064-014-1293-3","type":"journal-article","created":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T09:16:49Z","timestamp":1396084609000},"page":"2008-2017","source":"Crossref","is-referenced-by-count":132,"title":["On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson\u2019s Psychosis"],"prefix":"10.1007","volume":"39","author":[{"given":"Uli","family":"Hacksell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan S.","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger G.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,30]]},"reference":[{"key":"1293_CR1","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/mds.23714","volume":"26","author":"O Rascol","year":"2011","unstructured":"Rascol O, Lozano A, Stern M, Werner P (2011) Milestones in Parkinson\u2019s disease therapeutics. Mov Disord 26:1072\u20131082","journal-title":"Mov Disord"},{"key":"1293_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/NRL.0b013e31823d7abb","volume":"18","author":"O Bernal-Pacheco","year":"2012","unstructured":"Bernal-Pacheco O, Limotai N, GO CL, Fernandez HH (2012) Nonmotor manifestations in Parkinson\u2019s disease. Neurologist 18:1\u201316","journal-title":"Neurologist"},{"key":"1293_CR3","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1517\/14656566.2011.587122","volume":"12","author":"JG Goldman","year":"2009","unstructured":"Goldman JG, Vaughan CL, Goetz CG (2009) An update expert opinion on management and research strategies in Parkinson\u2019s disease psychosis. Expert Opin Pharmacother 12:2009\u20132024","journal-title":"Expert Opin Pharmacother"},{"key":"1293_CR4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1155\/2013\/645429","volume":"27","author":"JH Friedman","year":"2013","unstructured":"Friedman JH (2013) Parkinson disease psychosis: update. Behav Neurol 27:469\u2013477","journal-title":"Behav Neurol"},{"key":"1293_CR5","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","volume":"67","author":"EB Forsaa","year":"2010","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, Alves G (2010) A 12-year population-based study of psychosis in Parkinsons disease. Arch Neurol 67:996\u20131001","journal-title":"Arch Neurol"},{"key":"1293_CR6","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","volume":"43","author":"C Goetz","year":"1993","unstructured":"Goetz C, Stebbins G (1993) Risk factors for nursing home placement in advanced Parkinson\u2019s disease. Neurology 43:2227\u20132229","journal-title":"Neurology"},{"key":"1293_CR7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"The Parkinson Study Group","year":"1999","unstructured":"The Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med 340:757\u2013763","journal-title":"N Engl J Med"},{"key":"1293_CR8","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","volume":"353","author":"The French Clozapine Parkinson Study Group","year":"1999","unstructured":"The French Clozapine Parkinson Study Group (1999) Clozapine in drug-induced psychosis in Parkinson\u2019s disease. Lancet 353:2041\u20132042","journal-title":"Lancet"},{"key":"1293_CR9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNF.0b013e3181c47168","volume":"33","author":"AA Thomas","year":"2010","unstructured":"Thomas AA, Friedman JH (2010) Current use of clozapine in Parkinson disease and related disorders. Clin Neuropharmacol 33:14\u201316","journal-title":"Clin Neuropharmacol"},{"key":"1293_CR10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archneurol.2011.139","volume":"68","author":"D Weintraub","year":"2011","unstructured":"Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC (2011) Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 68:899\u2013904","journal-title":"Arch Neurol"},{"key":"1293_CR11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1756285610389656","volume":"3","author":"P Shobolt","year":"2010","unstructured":"Shobolt P, Samuel M, David A (2010) Quetiapine in the treatment of psychosis in Parkinson\u2019s disease. Ther Adv Neurol Disord 3:339\u2013350","journal-title":"Ther Adv Neurol Disord"},{"key":"1293_CR12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF02251294","volume":"110","author":"AL Nordstrom","year":"1993","unstructured":"Nordstrom AL, Farde L, Halldin C (1993) High 5-HT2A receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110:365\u2013367","journal-title":"Psychopharmacology"},{"key":"1293_CR13","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1176\/ajp.152.10.1444","volume":"152","author":"AL Nordstrom","year":"1995","unstructured":"Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444\u20131449","journal-title":"Am J Psychiatry"},{"key":"1293_CR14","first-page":"815","volume":"4","author":"DM Weiner","year":"2003","unstructured":"Weiner DM, Vanover KE, Brann MR, Meltzer HY, Davis RE (2003) Psychosis of Parkinson\u2019s disease: serotonin 2A receptor inverse agonists as potential therapeutics. Curr Opin Investig Drugs 4:815\u2013819","journal-title":"Curr Opin Investig Drugs"},{"key":"1293_CR15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","volume":"67","author":"B Ballanger","year":"2010","unstructured":"Ballanger B, Strafella AP, Eimeren T, Zurowski M, Rusjan PM, Houle S, Fox SH (2010) Serotonin 2A receptors and visual hallucinations in Parkinson\u2019s disease. Arch Neurol 67:416\u2013421","journal-title":"Arch Neurol"},{"key":"1293_CR16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1023\/A:1021169023731","volume":"38","author":"U Hacksell","year":"2002","unstructured":"Hacksell U, Nash N, Burstein ES, Pui F, Croston G, Brann M (2002) Chemical Genomics: massively parallel technologies for rapid lead identification and target validation. Cytotechnology 38:3\u201310","journal-title":"Cytotechnology"},{"key":"1293_CR17","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2174\/138161206776873662","volume":"12","author":"ES Burstein","year":"2006","unstructured":"Burstein ES, Piu F, Ma JN, Weissman JT, Currier EA, Nash NR, Weiner DM, Spalding TA, Schiffer HH, Del Tredici AL, Brann MR (2006) Integrative functional assays, chemical genomics and high throughput screening: harnessing signal transduction pathways to a common HTS readout. Curr Pharm Des 12:1717\u20131729","journal-title":"Curr Pharm Des"},{"key":"1293_CR18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1124\/mol.51.2.312","volume":"51","author":"ES Burstein","year":"1997","unstructured":"Burstein ES, Spalding TA, Brann MR (1997) Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol Pharmacol 51:312\u2013319","journal-title":"Mol Pharmacol"},{"key":"1293_CR19","doi-asserted-by":"crossref","first-page":"24322","DOI":"10.1074\/jbc.273.38.24322","volume":"273","author":"ES Burstein","year":"1998","unstructured":"Burstein ES, Spalding TA, Brann MR (1998) The second intracellular loop of the M5 muscarinic receptor is the switch which enables G protein coupling. J Biol Chem 273:24322\u201324327","journal-title":"J Biol Chem"},{"key":"1293_CR20","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0022-3565(25)12181-2","volume":"275","author":"TA Spalding","year":"1995","unstructured":"Spalding TA, Burstein ES, Brauner-Osborne H, Hill-Eubanks D, Brann MR (1995) Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis. J Pharmacol Exp Ther 275:1274\u20131279","journal-title":"J Pharmacol Exp Ther"},{"key":"1293_CR21","doi-asserted-by":"crossref","first-page":"21563","DOI":"10.1074\/jbc.273.34.21563","volume":"273","author":"TA Spalding","year":"1998","unstructured":"Spalding TA, Burstein ES, Henderson SC, Ducote KR, Brann MR (1998) Identification of a ligand-dependent switch within a muscarinic receptor. J Biol Chem 273:21563\u201321568","journal-title":"J Biol Chem"},{"key":"1293_CR22","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1074\/jbc.270.7.3141","volume":"270","author":"ES Burstein","year":"1995","unstructured":"Burstein ES, Spalding TA, Hill-Eubanks D, Brann MR (1995) Structure-function of muscarinic receptor coupling to G proteins. Random saturation mutagenesis identifies a critical determinant of receptor affinity for G proteins. J Biol Chem 270:3141\u20133146","journal-title":"J Biol Chem"},{"key":"1293_CR23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/10799890600567349","volume":"26","author":"TA Spalding","year":"2006","unstructured":"Spalding TA, Burstein ES (2006) Constitutive activity of muscarinic acetylcholine receptors. J Recept Signal Transduct Res 26:61\u201385","journal-title":"J Recept Signal Transduct Res"},{"key":"1293_CR24","doi-asserted-by":"crossref","first-page":"11441","DOI":"10.1074\/jbc.M111675200","volume":"277","author":"DA Shapiro","year":"2002","unstructured":"Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL (2002) Related evidence for a model of agonist-induced activation of 5-Hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem 277:11441\u201311449","journal-title":"J Biol Chem"},{"key":"1293_CR25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0022-3565(24)29327-7","volume":"299","author":"DM Weiner","year":"2001","unstructured":"Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DF, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR (2001) 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 299:268\u2013276","journal-title":"J Pharmacol Exp Ther"},{"key":"1293_CR26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/jpet.104.066688","volume":"310","author":"KE Vanover","year":"2004","unstructured":"Vanover KE, Harvey SC, Son TY, Bradley SR, Kold H, Makhay M, Veinbergs I, Spalding TA, Weiner DM, Andersson CM, Tolf BR, Brann MR, Hacksell U, Davis RE (2004) Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist. J Pharmacol Exp Ther 310:943\u2013951","journal-title":"J Pharmacol Exp Ther"},{"key":"1293_CR27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-2999(97)01188-6","volume":"335","author":"P Martin","year":"1997","unstructured":"Martin P, Waters N, Waters S, Carlsson A, Carlsson ML (1997) MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. Eur J Pharmacol 335:107\u2013116","journal-title":"Eur J Pharmacol"},{"key":"1293_CR28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0893-133X(98)00072-4","volume":"20","author":"GB Varty","year":"1999","unstructured":"Varty GB, Bakshi VP, Geyer MA (1999) M100907, a serotonin 5-HT2A antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20:311\u2013321","journal-title":"Neuropsychopharmacology"},{"key":"1293_CR29","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","volume":"317","author":"KE Vanover","year":"2006","unstructured":"Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE (2006) Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\u2019-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3S)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 317:910\u2013918","journal-title":"J Pharmacol Exp Ther"},{"key":"1293_CR30","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/FBP.0b013e32834aff98","volume":"22","author":"K McFarland","year":"2011","unstructured":"McFarland K, Price DL, Bonhaus DW (2011) Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson\u2019s disease. Behav Pharmacol 22:681\u2013692","journal-title":"Behav Pharmacol"},{"key":"1293_CR31","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0306-4522(03)00219-7","volume":"119","author":"A Balcioglu","year":"2003","unstructured":"Balcioglu A, Zhang K, Tarazi FI (2003) Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study. Neuroscience 119:1045\u20131053","journal-title":"Neuroscience"},{"key":"1293_CR32","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1523\/JNEUROSCI.3465-08.2008","volume":"28","author":"S Boulet","year":"2008","unstructured":"Boulet S, Mounayar S, Poupard A, Bertrand A, Jan C, Pessiglione M, Hirsch EC, Feuerstein C, Francois C, Feger J, Savasta M, Tremblay L (2008) Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis. J Neurosci 28:9575\u20139584","journal-title":"J Neurosci"},{"key":"1293_CR33","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1037\/0735-7044.101.6.806","volume":"101","author":"JP Bruno","year":"1987","unstructured":"Bruno JP, Jackson D, Zigmond MJ, Stricker EM (1987) Effect of dopamine-depleting brain lesions in rat pups: role of striatal serotonergic neurons in behavior. Behav Neurosci 101:806\u2013811","journal-title":"Behav Neurosci"},{"key":"1293_CR34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0304-3940(98)00198-0","volume":"245","author":"G Rozas","year":"1998","unstructured":"Rozas G, Liste I, Guerra MJ, Labandeira-Garcia JL (1998) Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett 245:151\u2013154","journal-title":"Neurosci Lett"},{"key":"1293_CR35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.physbeh.2007.05.033","volume":"92","author":"X Zhang","year":"2007","unstructured":"Zhang X, Andren PE, Svenningsson P (2007) Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson\u2019s disease model. Physiol Behav 92:29\u201333","journal-title":"Physiol Behav"},{"key":"1293_CR36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0006-8993(91)90553-8","volume":"556","author":"FC Zhou","year":"1991","unstructured":"Zhou FC, Bledsoe S, Murphy J (1991) Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res 556:108\u2013116","journal-title":"Brain Res"},{"key":"1293_CR37","doi-asserted-by":"crossref","unstructured":"Hubbard D, Hacksell U, McFarland K (2013) Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson\u2019s disease and Parkinson\u2019s disease psychosis: evaluation of therapeutic ratios. Behav Pharmacol (E pub)","DOI":"10.1097\/FBP.0b013e3283656db6"},{"key":"1293_CR38","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/0091270007299431","volume":"47","author":"KE Vanover","year":"2007","unstructured":"Vanover KE, Robbins-Weilert D, Wilbraham DG, Mant TG, van Kammen DP, Davis RE, Weiner DM (2007) Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. J Clin Pharmacol 47:704\u2013714","journal-title":"J Clin Pharmacol"},{"key":"1293_CR39","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/0091270007299361","volume":"47","author":"KE Vanover","year":"2007","unstructured":"Vanover KE, Robbins-Weilert D, Wilbraham DG, Mant TGK, van Kammen DP, Davis RE, Weiner DM (2007) The effects of food on the pharmacokinetics of a formulate ACP-103 tablet in healthy volunteers. J Clin Pharmacol 47:915\u2013919","journal-title":"J Clin Pharmacol"},{"key":"1293_CR40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145707007869","volume":"11","author":"AL Nordstrom","year":"2008","unstructured":"Nordstrom AL, Mansson M, Jovanovic H, Borg J, Karlsson P, Lonsdorf T, Halldin C, Farde L, Vanover KE, Hacksell U, Brann MR, Davis RE, Weiner DM (2008) PET analysis of the 5HT2A receptor inverse agonist ACP-103 in human brain. Int J Neuropsychopharm 11:163\u2013171","journal-title":"Int J Neuropsychopharm"},{"key":"1293_CR41","unstructured":"Weiner DM, Vanover KE, Hacksell U, Brann MR, Davis RE (2005) The tolerability of ACP-103, a 5-HT2A receptor inverse agonist, in Parkinson\u2019s disease patients. Abstract, 9th movement disorder society international congress, New Orleans"},{"key":"1293_CR42","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"HY Meltzer","year":"2010","unstructured":"Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH (2010) Pimavanserin, a serotonin2A receptor inverse agonist for the treatment of Parkinson\u2019s disease psychosis. Neuropsychopharmacology 35:881\u2013892","journal-title":"Neuropsychopharmacology"},{"key":"1293_CR43","doi-asserted-by":"crossref","unstructured":"Mills RG, Williams H, Bahr D (2011) Optimization of Phase III study design for pimavanserin in the treatment of Parkinson\u2019s disease psychosis. Abstract, XIX world congress on Parkinson\u2019s disease and related disorders, Shanghai, China","DOI":"10.1016\/S1353-8020(11)70600-9"},{"key":"1293_CR44","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/JGP.0b013e3181b0f8c0","volume":"17","author":"C Ballard","year":"2009","unstructured":"Ballard C, Brown R, Fossey J, Douglas S, Bradley P, Hancock J, James IA, Juszczak E, Bentham P, Burns A, Lindesay J, O\u2019Brien J, Bullock R, Johnson T, Holmes C, Howard R (2009) Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial). Am J Geriatr Psychiatry 17:726\u2013733","journal-title":"Am J Geriatr Psychiatry"},{"key":"1293_CR45","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.parkreldis.2012.10.022","volume":"19","author":"T Voss","year":"2013","unstructured":"Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H (2013) Performance of a shortened scale for assessment of positive symptoms for Parkinson\u2019s disease psychosis. Parkinsonism Relat Disord 19:295\u2013299","journal-title":"Parkinsonism Relat Disord"},{"key":"1293_CR46","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isacsson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C (2014) Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomized, placebo-controlled phase 3 trial. Lancet 383:533\u2013540","journal-title":"Lancet"},{"key":"1293_CR47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.sleep.2010.10.004","volume":"12","author":"S Anacoli-Israel","year":"2011","unstructured":"Anacoli-Israel S, Vanover KE, Weiner DM, Davis RE, vanKammen DP (2011) Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep Med 12:134\u2013141","journal-title":"Sleep Med"},{"key":"1293_CR48","unstructured":"Mills RG, Williams H, Chi-Burris K, Ballard C (2013) Long term pimavanserin treatment for Parkinson\u2019s disease psychosis (PDP): an interim analysis of safety and tolerability data from study ACP-103\u2013105. Abstract. 17th International congress of Parkinson\u2019s disease and movement disorders. June 16\u201320, Sydney, Australia"},{"key":"1293_CR49","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.schres.2012.07.029","volume":"141","author":"HY Meltzer","year":"2012","unstructured":"Meltzer HY, Elkis H, Vanover K, Weiner DM, vanKammen DP, Peters P, Hacksell U (2012) Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2\u00a0mg\/day, but does not enhance efficacy of haloperidol, 2\u00a0mg\/day:comparison with reference dose risperidone, 6\u00a0mg\/day. Schizophr Res 141:44\u2013152","journal-title":"Schizophr Res"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-014-1293-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-014-1293-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-014-1293-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T06:11:40Z","timestamp":1746166300000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-014-1293-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,30]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["1293"],"URL":"https:\/\/doi.org\/10.1007\/s11064-014-1293-3","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,30]]}}}